ArticleBreast (Edinburgh, Scotland)2026

BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer.

Timothé Guinel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.